In total, we identified five glioma conditions where FREM2 pathway PAL2 effectiveness was confirmed in two or more available datasets as OS or PFS predictor (Table 2): (i) for OS in LGG, (ii) for OS in LGG with methylated MGMT, (iii) for OS in LGG with unmethylated MGMT, (iv) for OS in LGG with IDH mutation; (v) for PFS in GBM. This evidence concerns the gene MGMT and central nervous system cancer.